@article{3107738,
    title = "Management of KPC-producing Klebsiella pneumoniae infections",
    author = "Bassetti, M. and Giacobbe, D.R. and Giamarellou, H. and Viscoli, C. and Daikos, G.L. and Dimopoulos, G. and De Rosa, F.G. and Giamarellos-Bourboulis, E.J. and Rossolini, G.M. and Righi, E. and Karaiskos, I. and Tumbarello, M. and Nicolau, D.P. and Viale, P.L. and Poulakou, G. and Critically Ill Patients Study Group of the European Society of Clinical Microbiology and Infectious Disease (ESCMID) and Hellenic Society of Chemotherapy (HSC) and Societa Italiana di Terapia Antinfettiva (SITA)",
    journal = "Clinical Microbiology and Infection",
    year = "2018",
    volume = "24",
    number = "2",
    pages = "133-144",
    publisher = "Elsevier B.V.",
    issn = "1198-743X",
    doi = "10.1016/j.cmi.2017.08.030",
    keywords = "beta lactam;  carbapenem derivative;  carbapenemase;  antiinfective agent;  bacterial protein;  beta lactamase;  carbapenemase, bacterial colonization;  critically ill patient;  high risk patient;  human;  infusion therapy;  Klebsiella pneumoniae infection;  matrix assisted laser desorption ionization time of flight mass spectrometry;  Medline;  meta analysis (topic);  nonhuman;  physician;  priority journal;  randomized controlled trial (topic);  Review;  systematic review (topic);  beta-lactam resistance;  drug effect;  enzymology;  Klebsiella infection;  Klebsiella pneumoniae;  metabolism, Anti-Bacterial Agents;  Bacterial Proteins;  beta-Lactam Resistance;  beta-Lactamases;  Humans;  Klebsiella Infections;  Klebsiella pneumoniae",
    abstract = "Background: Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae (KPC-KP) has become one of the most important contemporary pathogens, especially in endemic areas. Aims: To provide practical suggestion for physicians dealing with the management of KPC-KP infections in critically ill patients, based on expert opinions. Sources: PubMed search for relevant publications related to the management of KPC-KP infections. Contents: A panel of experts developed a list of 12 questions to be addressed. In view of the current lack of high-level evidence, they were asked to provide answers on the bases of their knowledge and experience in the field. The panel identified several key aspects to be addressed when dealing with KPC-KP in critically ill patients (preventing colonization in the patient, preventing infection in the colonized patient and colonization of his or her contacts, reducing mortality in the infected patient by rapidly diagnosing the causative agent and promptly adopting the best therapeutic strategy) and provided related suggestions that were based on the available observational literature and the experience of panel members. Implications: Diagnostic technologies could speed up the diagnosis of KPC-KP infections. Combination treatment should be preferred to monotherapy in cases of severe infections. For non–critically ill patients without severe infections, results from randomized clinical trials are needed for ultimately weighing benefits and costs of using combinations rather than monotherapy. Multifaceted infection control interventions are needed to decrease the rates of colonization and cross-transmission of KPC-KP. © 2017 European Society of Clinical Microbiology and Infectious Diseases"
}